Podcasts

Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.

Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.

Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.

Petros Grivas, MD, PhD, shares how he would treat a patient who presented with a new diagnosis of metastatic urothelial cancer and progressed after completing a gemcitabine-cisplatin chemotherapy regimen.

Margherita Rimini, MD, discusses findings from an analysis exploring the association between the BRCAness phenotype and response to platinum-based chemotherapy among patients with intrahepatic cholangiocarcinoma.

Ruth He, MD, discusses findings from a subgroup analysis which evaluated outcomes of patients with biliary tract cancer receiving durvalumab plus chemotherapy by primary tumor location: intrahepatic or extrahepatic cholangiocarcinoma or...

Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.

Petros Grivas, MD, shares results from the phase 2 TROPHY-U-01 trial evaluating the sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.

Robert Jones, MD, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following platinum-based chemotherapy for patients with metastatic urothelial carcinoma.

In part 2 of this 2-part podcast series, David O'Malley, MD, Ohio State University, discusses strategies for overcoming PARP inhibitor and platinum resistance in patients with ovarian cancer.